Quelling Qualms about Revlimid
Revlimid's survival data trumps secondary cancer risk in maintenance setting
Updated Phase III data on the use of Celgene Corp.'s Revlimid lenalidomide as maintenance therapy in multiple myeloma have quelled fears that the risk of second primary malignancies might outweigh the drug's survival benefit.
Questions about a possible association between Revlimid and second primary malignancies (SPMs) first cropped up at the American Society of Hematology meeting in December. The observations came from three ongoing Phase III trials in which higher rates of SPMs were